Yael R Symes1, Kurt M Ribisl2, Marcella H Boynton2, J Lee Westmaas3, Deborah K Mayer4, Shelley D Golden2. 1. Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA. yaelsymes@alumni.unc.edu. 2. Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA. 3. Behavioral Research Center, American Cancer Society, Atlanta, USA. 4. School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Abstract
PURPOSE: Cancer survivors who smoke cigarettes face health risks from continued smoking. Some smokers use e-cigarettes to reduce combustible cigarette use, but research on whether cancer survivors do the same is limited. Research is needed to understand whether smokers who are cancer survivors use e-cigarettes at higher rates than smokers never diagnosed with cancer, to inform provider-patient discussions about e-cigarettes. METHODS: Using cross-sectional data from current cigarette smokers in Wave 1 (2013-2014) of the Population Assessment of Tobacco Health (PATH) study, we compared cancer survivors (n = 433) and those without a prior cancer diagnosis (n = 10,872) on e-cigarette use and reasons for use. RESULTS: Among smokers, 59.4% of cancer survivors and 63.2% of those without a cancer diagnosis had ever used e-cigarettes, and nearly one-quarter of both groups (23.1% and 22.3%, respectively) reported being current users. Multivariate results, however, suggest that cancer survivors might be more likely to be ever (OR = 1.28; p = .05) or current (OR = 1.25; p = .06) e-cigarette users compared to those never diagnosed, although results were marginally significant. The majority of both groups (> 71%) reported using e-cigarettes for perceived health-related reasons-including smoking reduction. CONCLUSIONS: Our study found that among smokers, cancer survivors were using e-cigarettes at similar rates as never-diagnosed smokers and both groups used e-cigarettes largely for perceived health-related reasons. IMPLICATIONS FOR CANCER SURVIVORS: Clinicians who treat cancer survivors may need to routinely ask their patients who smoke about e-cigarette use and address the limited research on the efficacy of e-cigarettes as a cessation aid as compared to other evidence-based options.
PURPOSE:Cancer survivors who smoke cigarettes face health risks from continued smoking. Some smokers use e-cigarettes to reduce combustible cigarette use, but research on whether cancer survivors do the same is limited. Research is needed to understand whether smokers who are cancer survivors use e-cigarettes at higher rates than smokers never diagnosed with cancer, to inform provider-patient discussions about e-cigarettes. METHODS: Using cross-sectional data from current cigarette smokers in Wave 1 (2013-2014) of the Population Assessment of Tobacco Health (PATH) study, we compared cancer survivors (n = 433) and those without a prior cancer diagnosis (n = 10,872) on e-cigarette use and reasons for use. RESULTS: Among smokers, 59.4% of cancer survivors and 63.2% of those without a cancer diagnosis had ever used e-cigarettes, and nearly one-quarter of both groups (23.1% and 22.3%, respectively) reported being current users. Multivariate results, however, suggest that cancer survivors might be more likely to be ever (OR = 1.28; p = .05) or current (OR = 1.25; p = .06) e-cigarette users compared to those never diagnosed, although results were marginally significant. The majority of both groups (> 71%) reported using e-cigarettes for perceived health-related reasons-including smoking reduction. CONCLUSIONS: Our study found that among smokers, cancer survivors were using e-cigarettes at similar rates as never-diagnosed smokers and both groups used e-cigarettes largely for perceived health-related reasons. IMPLICATIONS FOR CANCER SURVIVORS: Clinicians who treat cancer survivors may need to routinely ask their patients who smoke about e-cigarette use and address the limited research on the efficacy of e-cigarettes as a cessation aid as compared to other evidence-based options.
Entities:
Keywords:
Cancer survivor; Dual use; E-cigarette; ENDS; PATH; Smoking
Authors: Ramzi G Salloum; Kayla R Getz; Andy S L Tan; Lisa Carter-Harris; Kelly C Young-Wolff; Thomas J George; Elizabeth A Shenkman Journal: Am J Prev Med Date: 2016-05-27 Impact factor: 5.043
Authors: Muhannad Malas; Jan van der Tempel; Robert Schwartz; Alexa Minichiello; Clayton Lightfoot; Aliya Noormohamed; Jaklyn Andrews; Laurie Zawertailo; Roberta Ferrence Journal: Nicotine Tob Res Date: 2016-04-25 Impact factor: 4.244
Authors: G E Richardson; M A Tucker; D J Venzon; R I Linnoila; R Phelps; J C Phares; M Edison; D C Ihde; B E Johnson Journal: Ann Intern Med Date: 1993-09-01 Impact factor: 25.391
Authors: Deesha Patel; Kevin C Davis; Shanna Cox; Brian Bradfield; Brian A King; Paul Shafer; Ralph Caraballo; Rebecca Bunnell Journal: Prev Med Date: 2016-09-07 Impact factor: 4.018
Authors: Kim-Anh Do; Marcella M Johnson; Dorota A Doherty; J Jack Lee; Xi Feng Wu; Qiong Dong; Waun K Hong; Fadlo R Khuri; Karen K Fu; Margaret R Spitz Journal: Cancer Causes Control Date: 2003-03 Impact factor: 2.506
Authors: G P Browman; G Wong; I Hodson; J Sathya; R Russell; L McAlpine; P Skingley; M N Levine Journal: N Engl J Med Date: 1993-01-21 Impact factor: 91.245
Authors: Ramzi G Salloum; Jinhai Huo; Ji-Hyun Lee; Juhan Lee; Jesse Dallery; Thomas George; Graham Warren Journal: PLoS One Date: 2019-12-09 Impact factor: 3.240